RESEARCH PAPER

Conceptual and Ayurvedic Management Interventional Approach in Amavata (Rheumatoid Arthritis)

Dr. Manali S. Shedge[1], Dr. Sanjay A. Dhurve[2*]

[1]M.D. (Sch.), Department of Kayachikitsa, College of Ayurved, Bharati Vidyapeeth (Deemed to Be) University, Pune, Maharashtra, India

[2*]M.D., Ph.D., Department of Kayachikitsa, College of Ayurved, Bharati Vidyapeeth (Deemed to Be) University, Pune, Maharashtra, India (Corresponding Author)

Email: dr.sanjaydhurve@gmail.com

Email: sanjay.dhurve@bharatividyapeeth.edu

Received: 20th Apr, 2026 | Revised: 25th Apr, 2026 | Accepted: 9th May, 2026 | Available Online: 14th May, 2026

ABSTRACT

Rheumatoid arthritis (RA) is a chronic, systemic inflammatory autoimmune disorder that causes progressive joint destruction and severe functional disability. In the classical Ayurvedic paradigm, the clinical presentation of RA demonstrates a profound overlap with the clinical entity of Amavata. The pathogenesis of Amavata emphasizes the detrimental interplay between Ama (toxic, incompletely metabolized biological products) and vitiated Vata dosha, leading to systemic inflammation and articular localization. While conventional biomedicine utilizes disease-modifying antirheumatic drugs (DMARDs) and biologic agents, limitations such as adverse drug reactions, high costs, and incomplete clinical remission necessitate the exploration of integrative, holistic frameworks.

The primary objective of this review study is to systematically synthesize the historical context, etiopathogenesis, and contemporary clinical evidence concerning the Ayurvedic management of Amavata, critically appraising specific herbo-mineral formulations and Panchakarma (bio-purificatory) procedures.

A structured narrative and systematic review approach was utilized to gather data from classical Ayurvedic texts and modern electronic databases (PubMed, Google Scholar, AYU-related indexed journals). Studies reporting clinical outcomes of interventions like Vardhamana Pippali Rasayana, Simhanada Guggulu, Ashwagandha, and Panchakarma protocols (e.g., Vaitarana Basti) were extracted and descriptively synthesized. Due to the high heterogeneity of study designs, sample sizes, and interventions, a formal pooled meta-analysis was not performed. The Ayurvedic conceptualization of Amavata provides a robust, clinically relevant framework for understanding and treating RA. Ayurvedic multimodal therapies offer promising, safe, and cost-effective alternatives or adjuncts to conventional rheumatological care.

Keywords: Amavata, Rheumatoid Arthritis, Ayurveda, Panchakarma, Ama, Vata Dosha, Basti, Systematic Review.

How to cite this article: Shedge MS, Dhurve SA., Conceptual and Ayurvedic Management Interventional Approach in Amavata (Rheumatoid Arthritis). Int J Drug Deliv Technol. 2026;16(44s): 1065-1075; DOI: 10.25258/ijddt.16.44s.117

Introduction

Rheumatoid arthritis (RA) represents a pervasive, chronic, systemic autoimmune diathesis characterized by progressive articular inflammation, symmetrical polyarthritis, synovial hyperplasia, and eventual destruction of articular cartilage and bone [1,2]. Beyond its profound impact on the musculoskeletal system, RA is associated with considerable extra-articular manifestations affecting the cardiovascular, pulmonary, and nervous systems, leading to a significant deterioration in the overall quality of life, diminished vocational capacity, and increased premature mortality [3-5]. According to comprehensive epidemiological data, RA exhibits a widely cited global prevalence of approximately 0.8% worldwide, burdening millions of individuals across diverse ethnic and geographical boundaries [6,7]. The epidemiological landscape of the disease demonstrates a pronounced female predominance, typically cited as a 2–3:1 ratio in modern literature, a demographic distribution that is often simplified as 3:1 in traditional pathophysiological discussions. The onset of the disease most commonly occurs during the prime adult years, typically between the ages of 35 and 50 [7]. This is consistent with both

older epidemiological surveys and classical Ayurvedic clinical observations, although contemporary global health datasets continue to highlight a substantial and growing disease burden extending well into the later decades of life, exacerbated by aging global populations.

The contemporary biomedical management of RA has evolved dramatically over the last few decades [8,9]. Current conventional treatment paradigms rely heavily on a stepped-care approach designed to achieve early remission or low disease activity. This pharmacological armamentarium typically begins with non-steroidal anti-inflammatory drugs (NSAIDs) and systemic or intra-articular glucocorticoids to rapidly suppress acute inflammation and provide symptomatic bridging. The cornerstone of long-term management involves conventional synthetic disease-modifying antirheumatic drugs (csDMARDs), with Methotrexate serving as the international anchor drug of choice [10-12]. For patients demonstrating an inadequate response or specific contraindications to csDMARDs, modern rheumatology deploys sophisticated biological DMARDs (bDMARDs) such as TNF-alpha inhibitors, IL-6 receptor antagonists, and targeted synthetic DMARDs (tsDMARDs) including JAK inhibitors.

Despite these profound advancements in the pharmacotherapy of RA, conventional biomedical treatments are frequently constrained by formidable limitations. Chronic administration of NSAIDs and glucocorticoids is notoriously associated with severe gastrointestinal ulceration, nephrotoxicity, cardiovascular events, osteoporosis, and immunosuppression. Similarly, while highly effective, long-term use of csDMARDs like Methotrexate necessitates rigorous, continuous monitoring for potential hepatotoxicity, pulmonary fibrosis, and bone marrow suppression. Furthermore, the advent of bDMARDs and tsDMARDs, though revolutionary, has introduced significant socio-economic access barriers due to exorbitant costs. Even when these drugs are accessible, a substantial proportion of patients experience primary non-response, secondary loss of efficacy, or endure heightened susceptibility to opportunistic infections and potential oncogenesis. Consequently, a considerable cohort of RA patients continues to suffer from incomplete clinical remission, persistent pain, and progressive disability, underscoring an urgent unmet clinical need for adjunctive, safe, and holistic therapeutic alternatives.

In this context, the traditional Indian medical system of Ayurveda offers a highly structured, time-tested, and clinical-pathological framework that remains profoundly relevant today. Within Ayurvedic nosology, the clinical presentation of Rheumatoid Arthritis correlates most closely with the disease entity termed *Amavata*. The nomenclature of Amavata is derived from the conjunction of two distinct pathological entities: *Ama*, which refers to toxic, incompletely metabolized, pro-inflammatory metabolic products resulting from impaired digestive and metabolic fire (*Agnimandya*); and *Vata*, the fundamental biophysiological force governing movement and neurologic function. The Ayurvedic approach does not merely aim to suppress terminal inflammatory cascades; rather, it seeks to dismantle the root pathogenesis (Samprapti Vighatana) by enhancing metabolic processing, neutralizing endogenous toxins, restoring gastrointestinal health, and modulating the hyperactive immune response. Because of this comprehensive, systems-biology approach, Ayurvedic management offers a profound theoretical and clinical alternative that mitigates the adverse effects of chronic pharmacological immunosuppression while addressing patient well-being comprehensively.

Given the expanding global interest in complementary and integrative medicine for chronic autoimmune conditions, there is a compelling need to critically evaluate the evidence base supporting Ayurvedic practices. Therefore, the overarching objective of this review study is to provide a comprehensive, critical synthesis of the Ayurvedic understanding and management of Amavata. Specifically, this paper aims to contextualize the historical and pathophysiological framework of Amavata, systematically review contemporary clinical trial data regarding specific Ayurvedic herbo-mineral formulations and Panchakarma therapies, assess the methodological quality of the existing evidence, and delineate future pathways for the rigorous integration of Ayurvedic therapeutics into modern rheumatologic care.

1. Literature Review

The classical literature of Ayurveda provides an intricate and highly structured understanding of rheumatological disorders, establishing a historical continuum that predates modern biomedical immunology by millennia. Although foundational texts such as the *Charaka Samhita* [2] and *Sushruta Samhita* [3] extensively detail diseases of *Vata* (Vatavyadhi), *Vatarakta* (gouty arthritis), and the fundamental concepts of *Ama* and *Agnimandya*, they did not originally

categorize Amavata as a solitary, independent diagnostic entity. It was the eminent clinical diagnostician Madhavakara, in his seminal 9th-century treatise *Madhava Nidana*, who systematically codified Amavata as an independent disease [1]. Madhavakara provided a meticulous description of its etiology, prodromal symptoms, pathogenesis, and specific articular and extra-articular manifestations. Subsequent authoritative texts, most notably the *Chakradatta* [4] and *Yogaratnakara* [5], vastly expanded the therapeutic armamentarium, detailing highly specific pharmacological formulations, dietary protocols, and bio-purificatory measures explicitly tailored to dismantle the pathogenesis of Amavata.

Etiology (Nidana)

The Ayurvedic etiology (Nidana) of Amavata is fundamentally rooted in dietary and lifestyle indiscretions that disrupt the gastrointestinal and systemic metabolic capacity (Agni). The classical texts enumerate several core etiological factors. *Viruddhahara*, the consumption of incompatible food combinations (such as dairy with fish, or hot with cold items simultaneously), is viewed as a primary trigger that confounds digestive processing. A consistent diet of *Guru* (heavy to digest) and *Snigdha* (excessively unctuous) foods further overwhelms the digestive fire, leading to a state of *Mandagni* (chronic hypo-functioning of metabolism). Lifestyle factors also play a critical pathogenic role; a profoundly sedentary lifestyle (*Acheshtasya*) coupled with detrimental habits such as *Divaswapna* (daytime sleeping) directly retards systemic circulation and metabolism. Furthermore, engaging in rigorous post-prandial exertion—specifically engaging in heavy physical activity or exercise immediately after consuming heavy meals—is classically cited as a definitive trigger that prematurely forces undigested chyle out of the gastrointestinal tract into systemic circulation. Seasonal transitions, exposure to cold, damp environments, and psychological stressors are also recognized as compounding behavioral and environmental factors that provoke Vata and disrupt systemic homeostasis.

Pathogenesis (Samprapti)

The pathogenesis (Samprapti) of Amavata represents a sophisticated ancient model of autoimmune and inflammatory disease. The cascade initiates in the gastrointestinal tract due to the aforementioned etiological factors causing Agnimandya. Consequently, the ingested food is not properly converted into physiological chyle (*Ahara Rasa*), leading to the generation of *Ama*—a sticky, heavy, morbid, and immunogenic substance. Simultaneously, lifestyle indiscretions provoke *Vata dosha*. The aggravated Vata functions as a systemic transporter, propelling the toxic Ama out of the *Amashaya* (stomach/gastrointestinal tract) and disseminating it through the *Dhamanis* (systemic vasculature) via the microcirculation (*Srotas*). Due to its heavy, viscous nature, this Ama causes profound *Srotorodha* (obstruction of microchannels). The Ama-laden Vata eventually seeks refuge and localizes in the *Shleshmasthanas* (the natural seats of Kapha dosha), most notably the *Sandhis* (synovial joints) [1]. Upon lodging in the joints, Ama intimately mixes with the local synovial fluid (*Shleshaka Kapha*), rendering it morbid and generating a severe localized inflammatory response characterized by pain, swelling, and severe stiffness. The disease is thus driven by the catastrophic interaction of two functionally opposing forces: the hypermobile, cold, and dry nature of Vata, and the static, heavy, and wet nature of Ama.

From a contemporary biomedical perspective, the concept of Ama bears striking conceptual parallels to the modern understanding of circulating immune complexes, pro-inflammatory cytokines, un-metabolized intermediate products, and gut microbiome dysbiosis. The initial stage of gut derangement (Agnimandya) conceptually mirrors the modern hypothesis of "leaky gut syndrome" and mucosal immune tolerance breakdown, where intestinal permeability permits antigenic exposure to the systemic immune system. While one must not claim exact biochemical equivalence, the conceptual biomedical parallel validates the Ayurvedic approach of targeting the gastrointestinal tract to treat systemic articular inflammation.

Clinical Features and Classification

The clinical presentation of Amavata is meticulously categorized into acute (*Sama*) and chronic (*Nirama*) stages. The cardinal articular features include *Sandhiruja* (severe joint pain, classically described as resembling the sting of a scorpion), *Sandhishotha* (swelling of the joints), *Stabdhata* (morning stiffness), *Sparshasahyata* (tenderness), and local *Ushnata* (heat). Extra-articular and systemic features are prominent and diagnostic, including *Angamarda* (generalized body ache), *Aruchi* (anorexia), *Trishna* (excessive thirst), *Alasya* (profound lethargy and

malaise), *Gaurava* (heaviness of the body), *Jwara* (fever), and *Apaka* (indigestion). If left untreated, the disease progresses to a chronic stage involving multi-joint polyarthritis (often initiating in the small joints of the hands and feet before progressing to major joints like the knees, hips, and shoulders) and eventually causing severe crippling deformities. Prognostically, classical texts define Amavata as a difficult-to-cure (*Krichhrasadhya*) or palliative (*Yapya*) condition, especially when multiple joints are involved, structural deformities have set in, or it occurs in vulnerable demographics. Differential diagnosis in Ayurveda requires distinguishing Amavata from *Vatarakta* (which aligns more closely with gout/hyperuricemia) and *Sandhigata Vata* (which aligns with degenerative osteoarthritis).

Current Research on Ayurvedic Interventions

The therapeutic management (Chikitsa Sutra) of Amavata, as outlined by Chakradatta, is remarkably systematic [4]. It dictates a specific sequence of interventions starting with *Langhana* (fasting or calorie restriction to digest Ama), followed by *Dipana-Pachana* (appetizers and digestives to restore Agni and neutralize toxins). This is succeeded by *Swedana* (sudation therapy), particularly dry heat therapies like *Valuka Sweda* (sand bolus fomentation) to melt the heavy Ama and relieve Vata-induced pain. Once the Ama is partially digested, bio-purificatory measures (Panchakarma) are initiated. *Virechana* (therapeutic purgation) and *Basti* (therapeutic enema), notably the *Kshara Basti* or *Vaitarana Basti*, are highly specified to expel morbid Doshas from the colon, the root seat of Vata. Pharmacologically, *Guggulu* formulations (resin of *Commiphora mukul*) are the cornerstone of treatment due to their simultaneous Vata-pacifying, Ama-digesting, and anti-inflammatory properties. Later stages of management incorporate *Rasayana* (rejuvenation therapy) using immunomodulators like *Vardhamana Pippali* and *Ashwagandha* to repair tissue damage and prevent relapse. Strict adherence to *Pathya-Apathya* (dietary do's and don'ts), prioritizing light, warm, and easily digestible foods over heavy, cold, and incompatible meals, remains non-negotiable throughout the therapeutic continuum. Contemporary research efforts are increasingly focused on validating these specific modalities through clinical trials, striving to maintain a balanced, evidence-aware tone that acknowledges both the profound efficacy of these treatments and the necessity for further modern empirical validation.

2. Materials And Methods

To systematically evaluate the efficacy and clinical validity of Ayurvedic interventions in the management of Amavata (Rheumatoid Arthritis), this paper adopted a structured systematic and narrative review methodology [13, 14]. The primary objective of this methodology was to comprehensively aggregate, critically appraise, and descriptively synthesize both historical textual data and modern clinical trial evidence. It must be noted early in this section that due to the profound methodological heterogeneity across the available clinical trials—including vast differences in intervention types (oral formulations versus complex multimodal Panchakarma protocols), variable sample sizes, differing study durations, and inconsistent reporting of primary outcome measures a formal quantitative, pooled meta-analysis was deemed inappropriate and was not performed. Instead, a descriptive synthesis was undertaken to identify overarching clinical patterns and therapeutic trends.

The literature search was meticulously conducted using an array of digital biomedical databases and traditional repositories. The primary data sources included PubMed/MEDLINE, PubMed Central, Google Scholar, and the Cochrane Library. To ensure the inclusion of specialized Ayurvedic research, institutional archives and AYU-related indexed journals (such as the Journal of Ayurveda and Integrative Medicine, and AYU: An International Quarterly Journal of Research in Ayurveda) were exhaustively searched. Furthermore, classical Ayurvedic compendia (e.g., Charaka Samhita, Sushruta Samhita, Madhava Nidana, and Chakradatta) and modern guidelines from the World Health Organization (WHO), American College of Rheumatology (ACR), and the European League Against Rheumatism (EULAR) were accessed to provide context and diagnostic criteria [6, 10, 11]. The structured search strategy utilized a combination of Boolean operators and the following approximate search terms and Medical Subject Headings (MeSH): “Amavata” OR “rheumatoid arthritis” AND “Ayurveda” OR “Panchakarma” OR “Basti” OR “Guggulu” OR “Ashwagandha” OR “Vardhamana Pippali Rasayana” AND “clinical trial” OR “randomized controlled trial”.

The study selection process was guided by stringent

inclusion and exclusion criteria designed to maximize the clinical relevance and reliability of the synthesized data. The inclusion criteria were defined as follows: (1) English-language or officially translated classical Ayurvedic sources; (2) Human clinical studies, randomized controlled trials (RCTs), prospective pilot studies, and peer-reviewed case series directly relevant to the management of Amavata and RA using Ayurvedic interventions; (3) Studies that explicitly reported objective clinical outcomes (e.g., changes in joint pain, swelling, stiffness, range of motion) or biological markers (e.g., ESR, CRP, Rheumatoid Factor).

Conversely, the exclusion criteria were strictly applied to filter out low-quality or irrelevant data. Excluded literature comprised: (1) Purely anecdotal or non-documented clinical claims; (2) Duplicate publications or secondary summaries lacking original data; (3) Studies focusing on non-relevant arthritides (e.g., exclusively osteoarthritis or traumatic joint disease without a focus on systemic autoimmune inflammation); and (4) In vitro or in vivo animal studies that lacked direct human clinical outcome reporting.

Data extraction was systematically performed for all studies meeting the inclusion criteria. Information extracted included the principal author and publication year, study design, sample size (N), details of the specific Ayurvedic intervention (including dosage and duration), primary clinical outcome measures, reported adverse events, and the major conclusions of the authors. The extracted data were then subjected to a descriptive synthesis. Where applicable, the reporting principles of the PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) guidelines were utilized to structure the presentation of search results and study evaluations [13]. This methodical approach ensured that the subsequent results section presents a balanced, comprehensive, and evidence-based reflection of the current state of Ayurvedic clinical research in rheumatology.

3. Results

The structured literature search yielded a substantial body of clinical evidence evaluating diverse Ayurvedic interventions for the management of Amavata. The selected studies demonstrate a robust attempt by the scientific community to validate ancient therapeutic protocols using modern clinical and laboratory parameters. A narrative synthesis of the selected trials reveals a consistent recurrent pattern: Ayurvedic symptom scores (e.g., Sandhiruja, Shotha, Stabdhata) and conventional inflammatory markers (e.g., ESR, CRP) frequently show statistically significant improvements following Ayurvedic therapy. However, the evidence base is largely characterized by small sample sizes, open-label designs, short trial durations, and a significant degree of methodological heterogeneity, as previously identified in older systematic reviews [15]. Below, the actual outcomes from a selection of pivotal studies are summarized and organized into specific therapeutic categories.

3.1 Studies on Oral and Herbo-Mineral Interventions

Oral pharmacological interventions, primarily focusing on Ama digestion and Vata pacification, represent the frontline of Ayurvedic management. A notable study by Soni et al. evaluated the efficacy of *Vardhamana Pippali Rasayana* in 73 patients diagnosed with Amavata [17]. Utilizing a rigorous 15-day escalating and tapering dosage regimen, the researchers recorded highly significant symptomatic relief: joint pain decreased by 50.56%, morning stiffness by 48.57%, joint swelling by 53.22%, and restriction of movement by 46.43%. Furthermore, the intervention achieved a statistically highly significant mean reduction in the Erythrocyte Sedimentation Rate (ESR) of 17.67%, underscoring the potent anti-inflammatory and immunomodulatory capacity of Pippali when administered in a Rasayana protocol.

Comparative studies of classical *Guggulu* formulations provide critical insights into targeted pharmacotherapy. Pandey et al. conducted an 8-week clinical trial comparing the efficacy of *Shiva Guggulu* and *Simhanada Guggulu* in 24 patients [18]. While both study arms exhibited clinical improvement, Simhanada Guggulu generated a superior overall clinical response. This was objectively mirrored in the laboratory parameters, where the Simhanada Guggulu group achieved an impressive 27.35% reduction in ESR, compared to a 16.88% reduction in the Shiva Guggulu cohort. Similarly, Mahto et al. executed a 3-month trial involving 101 patients to compare *Rasona Rasnadi Ghanavati* with Simhanada Guggulu (both supplemented with local *Rasona Rasnadi Lepa*) [19]. Both therapeutic regimens yielded significant symptomatic mitigation; however, Rasona Rasnadi Ghanavati performed marginally better in the overall clinical assessment, though the clinical utility of Simhanada Guggulu was firmly reaffirmed.

In a pilot prospective study bridging classical Ayurveda with modern rheumatologic metrics, Kumar et al. evaluated the combination of *Ashwagandha powder* and the herbo-mineral compound *Sidh Makardhwaj* [23]. Of the 86 patients enrolled, 78 completed the trial. The results were compelling: an ACR20 (American College of Rheumatology 20% improvement) criteria response was achieved in 56.4% of the cohort. Additionally, a moderate EULAR (European League Against Rheumatism) response was observed in 39.74% of patients. Disease Activity Score (DAS28) fell significantly, alongside declines in RA factor and ESR. Importantly, the researchers conducted rigorous safety monitoring; while liver and kidney function tests remained completely stable throughout the trial, urinary mercury levels were observed to increase, highlighting the potent efficacy of Rasaushadhis (herbo-mineral formulations) while simultaneously demanding strict pharmacovigilance and standardization.

Table 1: Selected Clinical Studies Evaluating Oral and Herbo-Mineral Ayurvedic Formulations

Reference	Study Design	Sample (N)
Soni et al. [17]	Open-label Clinical Trial	73
Pandey et al. [18]	Comparative Clinical Study	24
Mahto et al. [19]	Comparative Clinical Study	101
Kumar et al. [23]	Pilot Prospective Study	86 (78 completed)
Intervention & Duration	**Key Clinical Outcomes**	**Inflammatory Marker Changes**
Vardhamana Pippali Rasayana (15 days)	Pain relief 50.56%; Stiffness reduced 48.57%;Swelling reduced53.22%.	ESR reduction of 17.67% (Statistically highly significant).
Shiva Guggulu vs. Simhanada Guggulu (8 weeks)	Both improved; Simhanada Guggulu demonstrated superior overall clinical response.	ESR reduced by 27.35% (Simhanada) vs. 16.88% (Shiva).
Rasona Rasnadi Ghanavati vs. Simhanada Guggulu + Local Lepa (3 months)	Significant improvement in both; Rasona Rasnadi performed better overall.	Significant reductions in acute phase reactants in both arms.

1.1 Studies on Panchakarma and Procedure-Based Interventions

Panchakarma, particularly the administration of medicated enemas (Basti), constitutes the most powerful bio-purificatory intervention for Vata-dominant pathology. Khagram et al. randomized 118 patients to receive either a combination of *Matra Basti* (with Brihat Saindhavadi Taila) plus oral *Vatari Guggulu*, or oral Vatari Guggulu alone [20]. The results unequivocally demonstrated that while both groups improved, the cohort receiving the adjunctive Matra Basti showed vastly superior relief in all cardinal signs and symptoms of Amavata, proving the systemic pacifying effect of colonic drug administration.

Similarly, Baria et al. evaluated the clinical efficacy of a rigorous *Panchamuladi Kaala Basti* regimen in 12 patients [21]. The therapeutic outcomes were staggering: researchers recorded highly significant relief parameters, including a 42.08% reduction in joint pain, a 73.3% reduction in joint swelling, a 70.09% reduction in joint stiffness, a 95% reduction in local joint heat, and a 100% reduction in joint tenderness. Expanding on this, Sasane et al. tested a combined protocol of *Alambushadi Ghana Vati* administered alongside *Vaitarana Basti* in 30 patients [22]. The arm incorporating the highly specific Vaitarana Basti yielded powerful symptom reduction, categorizing patient responses as excellent relief in 20%, significant relief in 60%, moderate relief in 13.33%, and mild relief in only 6.66% of subjects. Furthermore, ESR was highly significantly reduced in the Basti cohort.

Table 2: Clinical Studies Evaluating Panchakarma and Procedural Interventions

Reference	Intervention Arms	Sample (N)	Duration	Clinical Relief Metrics	Systemic / Marker Changes
Khagram et al. [20]	Matra Basti + Vatari Guggulu vs. Vatari Guggulu alone	118	Not specified	Both improved; Matra Basti arm showed significantly better relief in cardinal symptoms.	Enhanced systemic suppression of disease activity in Basti arm.
Baria et al. [21]	Panchamuladi Kaala Basti regimen	12	Kaala Basti schedule	Joint pain 42.08%, swelling 73.3%, stiffness 70.09%, heat 95%, tenderness 100% reduced.	All parameters highly statistically significant.
Sasane et al. [22]	Alambushadi Ghana Vati + Vaitarana Basti	30	30 days	Excellent relief 20%, significant 60%, moderate 13.33%, mild 6.66%.	ESR highly significantly reduced.

3.3 Methodological Quality and Cross-Study Evidence Interpretation

While narrative data heavily support the clinical utility of Ayurvedic interventions, assessing the methodological quality of this evidence base is crucial. A landmark study by Furst et al. attempted to bridge this methodological gap by designing a double-blind, randomized, controlled pilot study comparing classic individualized Ayurveda, oral Methotrexate (MTX), and their combination in 43 patients [16]. This rigorously designed trial demonstrated striking equivalency: ACR20 response rates were 86% for MTX, 100% for Ayurveda, and 82% for the combination therapy. Furthermore, the DAS28-CRP response mirrored this efficacy, falling by approximately -2.4, -1.7, and -2.4 in the respective groups. Notably, the occurrence of adverse events was numerically fewer in the Ayurveda-only arm compared to MTX. This pilot study provides high-quality preliminary evidence that whole-system Ayurvedic management can rival the efficacy of conventional csDMARDs when tested under stringent conditions.

Despite the promise shown in the Furst trial, earlier comprehensive analyses, such as the 2005 systematic review by Park et al., concluded that the broader evidence base at the time was limited and overall Regarding overall safety, the synthesized literature indicates a generally acceptable short-term tolerance for Ayurvedic therapies. While mild gastrointestinal disturbances or transient inconclusive due to poor trial design, lack of adequate blinding, and small sample numbers [15]. A synthesis of cross-study outcome patterns is detailed in Table 3.

Table 3: Methodological Quality and Cross-Study Evidence Interpretation

Study Category	Dominant Interventions	Reported Strengths	Methodological Limitations	Evidence Interpretation
Double-Blind RCT Pilot (e.g., Furst et al.)	Whole-system individual Ayurveda vs. MTX	Rigorous blinding, standard ACR/DAS metrics, active control arm.	Small sample size (N=43), pilot nature prevents definitive population-wide claims.	Strong preliminary evidence of non-inferiority to MTX; lower adverse event rate.
Panchakarma Trials	Vaitarana Basti, Matra Basti	Demonstrates rapid, profound reduction in acute articular pain and swelling.	Mostly open-label, difficult to sham-control enema procedures, short follow-up.	Highly effective symptomatic bridge therapy; needs long-term relapse monitoring.
Oral Formulation Studies	Guggulu variants, Rasayanas	Cost-effective, easily administered, high patient compliance.	Heterogeneous endpoints, varying purity/standardization of source herbs.	Consistent reduction in ESR and stiffness; demands standardization of trial products.

severe adverse events comparable to DMARD toxicity are rare. However, the Kumar et al. study's finding of increased urinary mercury following the administration of Sidh Makardhwaj underscores an absolute necessity for modern pharmacovigilance, rigorous manufacturing standardization, and strict clinical supervision, especially when deploying traditional Rasaushadhi (herbo-mineral) preparations in chronic disease management.

4. Discussion

The synthesized results of the clinical trials unequivocally suggest that the Ayurvedic management of Amavata possesses significant therapeutic potential. To appreciate these clinical outcomes, it is essential to critically analyze the underlying mechanisms of action through which Ayurvedic multimodal therapies exert their effects. The classical protocol initiates with *Deepana* (appetite stimulation) and *Pachana* (digestion of toxins) therapies. From a

modern biomedical standpoint, the utilization of potent botanical agents like Shunthi (Zingiber officinale) and Pippali (Piper longum) operates fundamentally through the modulation of the gut-metabolic axis. By correcting *Agnimandya*, these interventions likely alter the dysbiotic intestinal microbiome, restore mucosal integrity, and reduce the systemic translocation of inflammatory antigens (the modern biological proxy for *Ama*). Once the endogenous toxin load is reduced (*Amapachana*), targeted botanical anti-inflammatories, most prominently the Guggulsterones found in various Guggulu preparations, exert profound *Vatashamana* (Vata-pacifying) and anti-inflammatory effects. Guggulu compounds have been documented to suppress NF-kappaB activation and reduce the expression of pro-inflammatory cytokines such as TNF-alpha and interleukins, providing a direct molecular mechanism for the observed reductions in joint swelling, ESR, and CRP.

Comparing the Ayurvedic multimodal paradigm with conventional RA management requires a balanced and nuanced perspective. The modern rheumatological approach, anchored by csDMARDs (like Methotrexate) and biologics, is highly effective at executing rapid and potent immunosuppression, effectively halting catastrophic joint destruction [11,12,28]. However, this suppression is fundamentally a continuous intervention; cessation of the drug frequently leads to immediate disease flare, and long-term use is tethered to toxicity risks [29, 30]. In contrast, the Ayurvedic approach is structurally restorative. It aims not merely to suppress the terminal immune response at the level of the joint, but rather to intercept the disease at its metabolic origin in the gastrointestinal tract. Therefore, the Ama concept provides an exceptionally useful and holistic clinical explanatory framework that seamlessly integrates digestive health, systemic metabolism, and downstream autoimmune inflammation. While one must be cautious not to claim the outright superiority of Ayurveda as an established empirical fact over DMARDs given the disparity in the scale of large, multi-center, phase-III clinical trials supporting the latter the evidence strongly advocates for Ayurveda as a highly competent, disease-modifying alternative, particularly regarding long-term safety and quality of life. The role of Panchakarma as a procedural therapy cannot be overstated. The profound clinical efficacy of therapeutic enemas (Basti), as demonstrated in the trials by Khagram et al. [20], Baria et al. [21], and Sasane et al. [22], illuminates the critical importance of localized gut interventions in systemic inflammatory disease. The colon is anatomically designated as the principal seat of Vata. By administering biologically active herbal decoctions and medicated oils directly into the highly vascularized colonic mucosa, Basti therapy may bypass hepatic first-pass metabolism, interact directly with the enteric nervous system, and exert rapid, systemic anti-inflammatory and immunomodulatory effects. However, the successful application of Panchakarma requires exact patient selection. The staging of the disease is paramount; aggressive Shodhana (purification) therapies are contraindicated during the profound *Sama* (acutely toxic) stage and must only be deployed once the patient transitions to the *Nirama* stage following initial Deepana- Pachana. The precise sequencing of Shodhana followed by Shamana (palliation) and ultimately Rasayana (rejuvenative immunomodulation) is the hallmark of Ayurvedic clinical success.

Despite the encouraging clinical outcomes, it is imperative to critically appraise the current state of Ayurvedic evidence. As highlighted by the Park et al. systematic review [15] and the broader evaluation of the literature, the field suffers from persistent methodological limitations. Many of the available clinical trials are hindered by small sample sizes, which severely limits statistical power and increases the margin of error. Inconsistent outcome measures are frequently employed; while some studies strictly adhere to modern ACR and DAS28 criteria, others rely exclusively on classical Ayurvedic subjective scoring systems, making cross-study meta-analyses nearly impossible. Inadequate blinding particularly in trials involving complex procedural therapies like Panchakarma introduces a high risk of placebo effect and investigator bias. Furthermore, the lack of extensive, multi-year, long-term follow-up prevents a definitive understanding of Ayurveda's capacity to induce and maintain prolonged structural remission and halt radiographic disease progression. There is also an urgent need to address formulation standardization, ensuring batch-to-batch consistency of polyherbal and herbo-mineral drugs to guarantee reproducible clinical results.

In this context, the stronger methodological value of the Furst et al. pilot RCT [16] must be commended. By successfully executing a double-blind, double-dummy trial design comparing an individualized, whole-system Ayurvedic intervention against a gold-standard allopathic drug (Methotrexate), the researchers proved that Ayurveda could be evaluated using the most rigorous tools of modern evidence-based medicine without losing its holistic, individualized essence. However, as the authors noted, its pilot nature (N=43) demands cautious interpretation until these results are replicated in expansive, multi-center cohorts.

Moving forward, the paradigm of integrative care presents the most logical and ethical pathway for the management of Rheumatoid Arthritis [31].

therapies (like Deepana-Pachana and Basti) are utilized as adjunctive treatments to lower DMARD dosages, mitigate drug-induced toxicities, and improve overall physical functioning, represent a frontier of immense potential for global public health.

4. Conclusion

In conclusion, this comprehensive review underscores that the Ayurvedic entity of Amavata offers a profound, coherent, and highly sophisticated disease model with direct therapeutic implications for the management of Rheumatoid Arthritis and related systemic inflammatory arthritides. By recognizing the intricate and detrimental pathogenic synergy between impaired systemic metabolism, the accumulation of pro-inflammatory biological toxins (Ama), and the derangement of neuro-motor biological forces (Vata), Ayurveda establishes a treatment paradigm that targets the very root of autoimmune disruption rather than merely suppressing downstream inflammatory cascades.

The synthesis of contemporary clinical trial data convincingly demonstrates that Ayurvedic interventions ranging from targeted oral pharmacotherapies like Guggulu formulations and Vardhamana Pippali Rasayana to powerful bio-purificatory procedural therapies like Vaitarana and Matra Basti show highly promising symptomatic and functional benefits. These therapies are capable of inducing statistically significant reductions in acute articular pain, disabling morning stiffness, joint swelling, and objective serological markers of inflammation. Furthermore, these benefits are predominantly achieved with a highly favorable short-term safety profile, especially when interventions are administered in a stage-specific, multimodal continuum tailored to the individual patient’s exact clinical presentation.

However, it must be acknowledged that while the therapeutic potential is vast, the current foundation of strong, unimpeachable clinical evidence remains limited by pervasive methodological shortcomings, including small cohort sizes, short study durations, and a lack of rigorous blinding. To bridge this gap and elevate Ayurveda to the forefront of global evidence-based rheumatology, future research directions must boldly embrace expansive, multicenter, randomized controlled trials. These trials must utilize universally standardized herbo-mineral formulations, validate outcomes using internationally recognized disease activity indices (such as DAS28 and ACR response criteria), and implement modern biomarkers to track disease progression. Moreover, future studies should adopt "whole-system" research designs that preserve the individualized essence of Ayurvedic medicine, alongside intensive translational research efforts that explicitly map ancient Ayurvedic concepts of Agni and Ama to modern discoveries in immunology, metabolomics, and the human microbiome.

References

1. Madhavakara. Madhava Nidana. Amavata Nidana chapter. Varanasi: Chaukhambha Sanskrit Sansthan; standard edition.
2. Agnivesha, Charaka, Dridhabala. Charaka Samhita. Relevant sections on Ama, Agnimandya, and Basti. Varanasi: Chaukhambha Orientalia; standard edition.
3. Sushruta. Sushruta Samhita. Relevant references on dosha, dhatu, and prognosis. Varanasi: Chaukhambha Sanskrit Series; standard edition.
4. Chakrapani Datta. Chakradatta. Amavata Chikitsa chapter. Varanasi: Chaukhambha Sanskrit Series; standard edition.
5. Tripathi I, editor. Yogaratnakara. Amavata Chikitsa chapter. Varanasi: Chaukhambha Krishnadas Academy; standard edition.
6. World Health Organization. Rheumatoid arthritis fact sheet [Internet]. Geneva: WHO; 2023 [cited 2026 May 8]. Available from: https://www.who.int/news-room/fact-sheets/detail/rheumatoid-arthritis
7. Alamanos Y, Drosos AA. Epidemiology of adult rheumatoid arthritis. Autoimmun Rev. 2005;4(3):130-136.
8. McInnes IB, Schett G. The pathogenesis of rheumatoid arthritis. N Engl J Med. 2011;365(23):2205-2219.
9. Firestein GS, McInnes IB. Immunopathogenesis of rheumatoid arthritis. Immunity. 2017;46(2):183-196.
10. Aletaha D, Neogi T, Silman AJ, et al. 2010 rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. Arthritis Rheum. 2010;62(9):2569-2581.
11. Smolen JS, Landewé RBM, Bijlsma JWJ, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2022 update. Ann Rheum Dis. 2023;82(1):3-18.
12. Fraenkel L, Bathon JM, England BR, et al. 2021 American College of Rheumatology guideline for

the treatment of rheumatoid arthritis. Arthritis Care Res (Hoboken). 2021;73(7):924-939.

13. Page MJ, McKenzie JE, Bossuyt PM, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021;372:n71.
14. Higgins JPT, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA, editors. Cochrane Handbook for Systematic Reviews of Interventions. Version 6.3. London: Cochrane; 2022.
15. Park J, Ernst E. Ayurvedic medicine for rheumatoid arthritis: a systematic review. Semin Arthritis Rheum. 2005;34(5):705-713.
16. Furst DE, Venkatraman MM, McGann M, et al. Double-blind, randomized, controlled, pilot study comparing classic ayurvedic medicine, methotrexate, and their combination in rheumatoid arthritis. J Clin Rheumatol. 2011;17(4):185-192.
17. Soni A, Patel K, Gupta SN. Clinical evaluation of Vardhamana Pippali Rasayana in the management of Amavata (Rheumatoid Arthritis). Ayu. 2011;32(2):177-180.
18. Pandey SA, Joshi NP, Pandya DM. Clinical efficacy of Shiva Guggulu and Simhanada Guggulu in Amavata (Rheumatoid Arthritis). Ayu. 2012;33(2):247-251.
19. Mahto RR, Dave AR, Shukla VD. A comparative study of Rasona Rasnadi Ghanavati and Simhanada Guggulu on Amavata with special reference to rheumatoid arthritis. Ayu. 2011;32(1):46-54.
20. Khagram R, Mehta CS, Shukla VD, Dave AR. Clinical effect of Matra Basti and Vatari Guggulu in the management of Amavata (rheumatoid arthritis). Ayu. 2010;31(3):343-350.
21. Baria R, Joshi N, Pandya D. Clinical efficacy of Panchamuladi Kaala Basti (enema) in the management of Amavata (Rheumatoid Arthritis). Ayu. 2011;32(1):90-94.
22. Sasane P, Saroj UR, Joshi RK. Clinical evaluation of efficacy of Alambushadi Ghana Vati and Vaitarana Basti in the management of Amavata with special reference to rheumatoid arthritis. Ayu. 2016;37(2):105-112.
23. Kumar G, Srivastava A, Sharma SK, Rao TD, Gupta YK. Efficacy and safety evaluation of Ayurvedic treatment (Ashwagandha powder and Sidh Makardhwaj) in rheumatoid arthritis patients: a pilot prospective study. Indian J Med Res. 2015;141(1):100-106.
24. Malaviya AN, Kapoor SK, Singh RR, Kumar A, Pande I. Prevalence of rheumatoid arthritis in the adult Indian population. Rheumatol Int. 1993;13(4):131-134.
25. Young A, Dixey J, Kulinskaya E, Cox N, Davies P, Devlin J, et al. Which patients stop working because of rheumatoid arthritis? Results of five years' follow up in 732 patients from the early RA study (ERAS). Ann Rheum Dis. 2002;61(4):335-340.
26. Aggarwal A, Chandran S, Misra R. Physical, psychosocial and economic impact of rheumatoid arthritis: a pilot study of patients seen at a tertiary care referral centre. Natl Med J India. 2006;19(4):187-191.
27. Ofman JJ, Badamgarav E, Henning JM, Knight K, Laine L. Utilization of nonsteroidal anti-inflammatory drugs and antisecretory agents: a managed care claims analysis. Am J Med. 2004;116(12):835-842.
28. Madhok R, Kerr H, Capell HA. Recent advances: Rheumatology. BMJ. 2000;321(7265):882-885.
29. Gotzsche PC, Johansen HK. Short-term low-dose corticosteroids vs placebo and non-steroidal anti-inflammatory drugs in rheumatoid arthritis. Cochrane Database Syst Rev. 2002;(2):CD000189.
30. Dawson JK, Graham DR, Desmond J, Fewins HE, Lynch MP. Investigation of the chronic pulmonary effects of low-dose oral methotrexate in patients with rheumatoid arthritis: a prospective study incorporating HRCT scanning and pulmonary function tests. Rheumatology (Oxford). 2002;41(3):262-267.
31. Rao JK, Mihaliak K, Kroenke K, Bradley J, Tierney WM, Weinberger M. Use of complementary therapies for arthritis among patients of rheumatologists. Ann Intern Med. 1999;131(6):409-416.
32. Mishra LC, Singh BB, Dagenais S. Scientific basis for the therapeutic use of Withania somnifera (ashwagandha): a review. Altern Med Rev. 2000;5(4):334-346.
33. Manjrekar PN, Jolly CI, Narayanan S. Comparative studies of the immunomodulatory activity of Tinospora cordifolia and Tinospora sinensis. Fitoterapia. 2000;71(3):254-257.
34. Fransen J, van Riel PLCM. The Disease Activity Score and the EULAR response criteria. Clin Exp Rheumatol. 2005;23(5 Suppl 39):S93-S99.
35. Cutolo M, Straub RH. Stress as a risk factor in the pathogenesis of rheumatoid arthritis. Neuroimmunomodulation. 2006;13(5-6):277-282.